10/27 Taiwan BIO Weekly
2026-10-27 |
| Taiwan BIO Weekly |
| Pharmaceutical Industry Associations Push to Accelerate Generic Drug Market Entry 26 October, 2026 Pharmaceutical and biotechnology patent disputes are spreading from overseas markets to Taiwan's domestic market. Taiwanese pharmaceutical companies, including TAHO Pharmaceuticals (TW: 6467), Orient Pharma (TW: 4166), Handa Pharmaceuticals (TW: 6620), Mycenax Biotech (TW: 4726), and EirGenix (TW: 6589), have increasingly faced patent disputes with international drugmakers. Meanwhile, local pharmaceutical industry associations are actively advocating amendments to the Pharmaceutical Affairs Act to improve the patent linkage system, accelerate the market entry of domestically developed generic drugs, and ensure fair competition. More... (in Chinese) |
| Bio Preventive Medicine's DNlite Kidney Function Test Expands into Mid-to-Large Hospitals 26 October, 2026 Bio Preventive Medicine (TW: 6810) announced that its proprietary precision kidney function test, DNlite, has received approval for self-pay testing at regional hospitals and higher-level medical institutions in Taiwan, enabling expansion beyond primary care clinics and health screening centers. The approval marks a key commercialization milestone, supporting broader clinical adoption and strengthening the company's growth potential. More... (in Chinese) |
| Adimmune Enters Peak Vaccine Shipment Season 21 October, 2026 Adimmune (TW: 4142) expects revenue to peak during the flu vaccine shipment season, supported by growing CDMO orders and its transition into a high-value CDMO and technology services provider. CDMO manufacturing accounts for 67% of revenue, while technology services contribute 16%. Analysts forecast 50% growth in vaccine orders from major international clients in 2026, with further expansion in 2027. The company is also expanding its biosimilar CDMO business, supported by regulatory approvals in Japan and the UK in 2026, with US shipments expected to begin in 2027. More... (in Chinese) |
| TLC BioSciences' Long-Acting Pain Drug Meets Phase III Trial Endpoints 20 October, 2026 TLC BioSciences (TW: 7924) reported positive Phase III results for TLC590, its long-acting postoperative pain drug, in bunion surgery patients. The trial met its primary endpoint, significantly reducing pain and opioid use within 72 hours versus placebo. TLC590 also outperformed Exparel (liposomal bupivacaine) in pain relief and opioid reduction, while providing significantly better seven-day pain control than both comparators, highlighting its potential as a non-opioid pain management option. More... (in Chinese) |
| TAHO Pharmaceuticals Goes Public, Eyes Growth from US and European Drug Approvals 20 October, 2026 TAHO Pharmaceuticals (TW: 6467) officially debuted on the stock exchange on the 20th of October at an offering price of NT$105.6 per share. Leveraging its proprietary Trans-Epithelial Drug Delivery System (TDS), the company focuses on developing novel drug formulations under the 505(b)(2) regulatory pathway. Its business model emphasizes value validation and strategic licensing, generating long-term revenue through upfront licensing fees, milestone payments, and sales royalties. More... (in Chinese) |
| Biphasic Cartilage-Bone Repair Technology: From Clinical Need to Global Markets Press release 19 October, 2026 Articular cartilage has limited capacity for self-repair, making simultaneous regeneration of cartilage and underlying bone a key challenge in orthopedic regenerative medicine. ITRI's Biomedical Technology and Device Research Laboratories partnered with National Taiwan University Hospital (NTUH) to develop a biphasic osteochondral repair technology integrating biomaterials, tissue engineering, and clinical orthopedics. More... |
| From Investing in Prevention to Building Health Resilience 19 October, 2026 Vaccination policy is no longer solely a means of preventing illness: It has become foundational to extending healthy life expectancy, easing the burden on the healthcare system, and strengthening national health resilience. More... |
| TaiGen Continues ASEAN Expansion as Vietnam Accepts Taigexyn Applications for Two Formulations 18 October, 2026 TaiGen Biotechnology (TW: 4157) announced that Vietnam's Drug Administration (DAV) has accepted New Drug Applications (NDAs) for the oral and intravenous formulations of its antibiotic Taigexyn (nemonoxacin), submitted by partners Newsun Pharmaceutical JSC and Fideschem for the treatment of community-acquired pneumonia. The review timeline and final approval will be subject to DAV's regulatory procedures. More... (in Chinese) |
| Taiwan's Jyong Biotech to establish new manufacturing facility and US operations center in Texas 16 October, 2026 Jyong Biotech, a Taiwan-based science-driven biotechnology company dedicated to the development and commercialisation of innovative plant-derived therapeutics, has announced that it plans to establish a potential new manufacturing facility and US operations center in Texas. More... |
| T-E Meds and Anivance AI Showcase ADC and NAMs Research at World ADC Congress 16 October, 2026 T-E Meds, a subsidiary of T-E Pharma, presented preclinical progress on its antibody-drug conjugate (ADC) candidate TE-1146 at the World ADC Congress in San Diego. Developed for multiple myeloma, TE-1146 combines a daratumumab-derived anti-CD38 antibody with lenalidomide through site-specific conjugation. The presentation also highlighted safety assessments conducted with Taiwan's Anivance AI using New Approach Methodologies (NAMs), underscoring T-E Meds' strategy to evaluate therapeutic efficacy and identify potential human safety risks early in drug development. More... (in Chinese) |
| From Taiwan to the World: PharmaEssentia Builds a Scientist-Led, Fully Integrated Global Biopharmaceutical Company with Patients at Its Core Press release 16 October, 2026 PharmaEssentia Corporation (TW: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clinical trials and overseas investments, as it seeks to bring its Taiwan-developed innovative new drug to more international markets. More... |
| From Hospital AI to Home Monitoring: Taiwan's Health-Tech Sector Tests Its US Market Fit in Dallas Press release 14 October, 2026 Taiwan's healthcare technology sector has no shortage of devices, AI models or clinical data. The harder question is what happens when those technologies leave Taiwan: whether they can validate across different patient populations, clear US regulatory requirements, fit American clinical workflows and find partners capable of deploying and servicing them locally. More... |
| ========================================= |
| Please note that Taiwan BIO is not responsible for the accuracy of third-party news stories covered in this newsletter. |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2027 (27-31 July, 2027) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |